BCG remains the only widely available vaccine for TB. Yet the development of a COVID-19 vaccine over the last year shows that there is capacity to rapidly create new vaccines.
L’expertise universitaire, l’exigence journalistique
Articles sur BCG100
Ensemble des articles
Until vaccines that are capable of protecting all populations against TB are developed, treatment is the best option to preventing infection.
South Africa’s long-awaited TB prevalence survey results were recently released. They reveal that the country has a much higher burden of TB than previously thought.
Tuberculosis is a global threat and a public health concern on a scale similar to COVID-19.
Les contributeurs les plus fréquents
-
Head of the Centre of Excellence for Biomedical TB Research, University of the Witwatersrand
-
Assistant Professor, Africa Health Research Institute (AHRI)
-
Senior Research Fellow, James Cook University
-
Professor of International Health at LSHTM and Member of Faculty, Africa Health Research Institute (AHRI)
-
Lead Senior Scientist, Aurum Institute
